Serum complement in eclamptogenic toxemia

Prall, Robert H.; Kantor, Fred S.

doi:10.1016/0002-9378(66)90145-1

Cited by 16 publications

(8 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The elevation of the complement fractions A-C is not consistent with the results of Prall and Kantor (1966) who, by measuring one of the many complement components, found no change in serum C' in uncomplicated pregnancies. In the present study the two complement fractions measured in the postpartum specimen are predominantly in the form of PIC but following storage of the pregnancy serum for three months most of this had dissociated into the faster moving inactive PIA globulin.…”

Section: A Study Of Serum Protein Changes In Late Pregnancy 49contrasting

confidence: 89%

A Study of Serum Protein Changes in Late Pregnancy and Identification of the Pregnancy Zone Protein Using Antigen Antibody Crossed Immunoelectrophoresis

Studd

Blainey

Bailey

1970

BJOG

View full text Add to dashboard Cite

Section: A Study Of Serum Protein Changes In Late Pregnancy 49contrasting

confidence: 89%

A Study of Serum Protein Changes in Late Pregnancy and Identification of the Pregnancy Zone Protein Using Antigen Antibody Crossed Immunoelectrophoresis

Studd

Blainey

Bailey

1970

BJOG

View full text Add to dashboard Cite

“…Previous studies of complement system in preeclampsia found no differences[136,142,143] in serum complement hemolytic activity (CH 50 ) in women with preeclampsia. In contrast, Haeger et al[144] reported in a cross-sectional study that plasma C3a and C5a concentrations in patients with preeclampsia were higher than in normal pregnant women at the time of delivery.…”

Section: Discussionmentioning

confidence: 88%

“…[134,135] However, the association between complement system and preeclampsia, through the determination of various complement proteins, has been addressed in the past with conflicting results. [136–139] Although preeclampsia and SGA share common features, there is a paucity of data on maternal plasma complement activation in women with SGA with or without preeclampsia. This study was design to determine if the maternal plasma anaphylatoxin C3a, C4a and C5a concentrations in women with SGA neonates are different from those with preeclampsia.…”

Section: Introductionmentioning

confidence: 99%

Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products

Soto¹,

Romero²,

Richani³

et al. 2009

The Journal of Maternal-Fetal & Neonatal Medicine

View full text Add to dashboard Cite

Objective The activation of the complement system results in the generation of split products with pro-inflammatory properties. The objective of this study was to determine whether preeclampsia and SGA are associated with changes in the maternal plasma concentrations of anaphylatoxins C3a, C4a and C5a. Methods A cross-sectional study was conducted in the following groups: a) normal pregnant women (n=134); b) women who delivered an SGA neonate (n=53); and c) preeclampsia with (n=52) and without SGA (n=54). Maternal plasma anaphylatoxin concentrations were determined by ELISA. Results 1) Women with preeclampsia with or without SGA had a significantly higher median plasma C5a concentration than that of normal pregnant women and those with SGA alone (all p<0.01); 2) women with SGA alone did not have an increase in plasma C5a concentration; 3) in contrast, the median maternal plasma concentration of C4a was lower in women with preeclampsia and SGA than that of those with a normal pregnancy (p=0.001); 4) no changes in C3a were observed among the study groups. Conclusion Preeclampsia is associated with increased plasma concentration of C5a, regardless of the presence or absence of an SGA fetus. In contrast, there was no difference in the plasma C3a, C4a and C5a concentration in patients with SGA.

show abstract

“…After delivery, C3 returned to early pregnancy values (Baines et al, 1974). Earlier studies are contradictory with no change in complement noted over the course of pregnancy (Prall and Kantor, 1966). Total hemolytic complement is a relatively insensitive measure and significant complement activation can occur with little change in this measure.…”

Section: Complement System and Normal Pregnancymentioning

confidence: 94%

The complement system and adverse pregnancy outcomes

Regal

Gilbert

Burwick

2015

Molecular Immunology

135

115

View full text Add to dashboard Cite

Adverse pregnancy outcomes significantly contribute to morbidity and mortality for mother and child, with lifelong health consequences for both. The innate and adaptive immune system must be regulated to insure survival of the feta allograft, and the complement system is no exception. An intact complement system optimizes placental development and function and is essential to maintain host defense and fetal survival. Complement regulation is apparent at the placental interface from early pregnancy with some degree of complement activation occurring normally throughout gestation. However, a number of pregnancy complications including early pregnancy loss, fetal growth restriction, hypertensive disorders of pregnancy and preterm birth are associated with excessive or misdirected complement activation, and are more frequent in women with inherited or acquired complement system disorders or complement gene mutations. Clinical studies employing complement biomarkers in plasma and urine implicate dysregulated complement activation in components of each of the adverse pregnancy outcomes. In addition, mechanistic studies in rat and mouse models of adverse pregnancy outcomes address the complement pathways or activation products of importance and allow critical analysis of the pathophysiology. Targeted complement therapeutics are already in use to control adverse pregnancy outcomes in select situations. A clearer understanding of the role of the complement system in both normal pregnancy and complicated or failed pregnancy will allow a rational approach to future therapeutic strategies for manipulating complement with the goal of mitigating adverse pregnancy outcomes, preserving host defense, and improving long term outcomes for both mother and child.

show abstract

Serum complement in eclamptogenic toxemia

Cited by 16 publications

References 11 publications

A Study of Serum Protein Changes in Late Pregnancy and Identification of the Pregnancy Zone Protein Using Antigen Antibody Crossed Immunoelectrophoresis

A Study of Serum Protein Changes in Late Pregnancy and Identification of the Pregnancy Zone Protein Using Antigen Antibody Crossed Immunoelectrophoresis

Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products

The complement system and adverse pregnancy outcomes

Contact Info

Product

Resources

About